420 related articles for article (PubMed ID: 19798756)
1. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Brent DA
Depress Anxiety; 2009; 26(10):871-4. PubMed ID: 19798756
[No Abstract] [Full Text] [Related]
2. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Brent DA; Emslie GJ; Clarke GN; Asarnow J; Spirito A; Ritz L; Vitiello B; Iyengar S; Birmaher B; Ryan ND; Zelazny J; Onorato M; Kennard B; Mayes TL; Debar LL; McCracken JT; Strober M; Suddath R; Leonard H; Porta G; Keller MB
Am J Psychiatry; 2009 Apr; 166(4):418-26. PubMed ID: 19223438
[TBL] [Abstract][Full Text] [Related]
3. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Brent D; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller M; Vitiello B; Ritz L; Iyengar S; Abebe K; Birmaher B; Ryan N; Kennard B; Hughes C; DeBar L; McCracken J; Strober M; Suddath R; Spirito A; Leonard H; Melhem N; Porta G; Onorato M; Zelazny J
JAMA; 2008 Feb; 299(8):901-913. PubMed ID: 18314433
[TBL] [Abstract][Full Text] [Related]
4. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
5. A depressed adolescent at high risk of suicidal behavior.
Vitiello B; Pearson JL
Am J Psychiatry; 2008 Mar; 165(3):323-8; quiz 408. PubMed ID: 18316430
[No Abstract] [Full Text] [Related]
6. TORDIA: unique opportunity to explore half-life theory.
Smith E
Am J Psychiatry; 2009 Aug; 166(8):936; author reply 936-7. PubMed ID: 19651756
[No Abstract] [Full Text] [Related]
7. Teenaged, depressed, and treatment resistant: what predicts self-harm?
Weissman MM
Am J Psychiatry; 2009 Apr; 166(4):385-7. PubMed ID: 19339360
[No Abstract] [Full Text] [Related]
8. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
Asarnow JR; Emslie G; Clarke G; Wagner KD; Spirito A; Vitiello B; Iyengar S; Shamseddeen W; Ritz L; Birmaher B; Ryan N; Kennard B; Mayes T; DeBar L; McCracken J; Strober M; Suddath R; Leonard H; Porta G; Keller M; Brent D
J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):330-339. PubMed ID: 19182688
[TBL] [Abstract][Full Text] [Related]
9. Re: Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression.
Al-Adwani A
Can J Psychiatry; 2005 Nov; 50(13):877; author reply 877-8. PubMed ID: 16483124
[No Abstract] [Full Text] [Related]
10. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
[TBL] [Abstract][Full Text] [Related]
11. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
13. Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression.
Benazzi F
Can J Psychiatry; 2005 Mar; 50(3):184. PubMed ID: 15830829
[No Abstract] [Full Text] [Related]
14. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
Hetrick S; Merry S; McKenzie J; Sindahl P; Proctor M
Cochrane Database Syst Rev; 2007 Jul; (3):CD004851. PubMed ID: 17636776
[TBL] [Abstract][Full Text] [Related]
15. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
16. Agomelatine: new drug. Adverse effects and no proven efficacy.
Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G
Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853
[TBL] [Abstract][Full Text] [Related]
18. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
Sheehan DV; Nemeroff CB; Thase ME; Entsuah R;
Int Clin Psychopharmacol; 2009 Mar; 24(2):61-86. PubMed ID: 19238088
[TBL] [Abstract][Full Text] [Related]
19. New antidepressants for older people: a critical review of the evidence base.
Katona C
Encephale; 2008 Apr; 34 Suppl 2():S71-S76. PubMed ID: 18675006
[No Abstract] [Full Text] [Related]
20. Venlafaxine versus fluoxetine.
Paton C
J Clin Psychiatry; 1999 Oct; 60(10):708. PubMed ID: 10549691
[No Abstract] [Full Text] [Related]
[Next] [New Search]
